Development of low-dose reproductive hormone therapies in China

被引:26
作者
Ge, Qinsheng [1 ]
Tian, Qinjie
Tseng, Hung
Naftolin, Frederick
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol,Div Reprod Endocrinol, Beijing 100730, Peoples R China
[2] Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Dermatol Cell & Dev Biol, Philadelphia, PA 19104 USA
[4] NYU, Dept Obstet & Gynecol, New York, NY 10016 USA
关键词
menopause; estrogen; Women's Health Initiative; Nurses' Health Study; cardioprotection; computed tomographic angiography;
D O I
10.1080/09513590601005912
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A historical account is presented of the development of sex hormone treatment from its beginning at the Peking Union Medical College to its present-day generalization throughout China. The general theme of this work has been to test low-dose hormone regimens. Notable successes include low-dose oral contraception and menopausal hormone treatment. In support of the latter, we present a new clinical study of the effects of low-dose, intermittent, patient-metered hormone replacement therapy (HRT), which shows decreased menopausal symptoms, maintenance of bone health and height, and improved cardiovascular status compared with untreated controls. Cardiovascular testing, included carotid artery ultrasound scanning and computed tomographic coronary angiography, supports a cardioprotective effect of long-term (up to 31 years) low-dose HRT that is begun during the menopausal transition. These results highlight the urgent need for larger, prospective trials of long-term low-dose HRT started during the perimenopausal period.
引用
收藏
页码:636 / 645
页数:10
相关论文
共 31 条
[1]   The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women [J].
Alexandersen, P ;
Tankó, LB ;
Bagger, YZ ;
Qin, G ;
Christiansen, C .
CLIMACTERIC, 2006, 9 (02) :108-118
[2]   Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding [J].
Archer, DF ;
Dorin, M ;
Lewis, V ;
Schneider, DL ;
Pickar, JH .
FERTILITY AND STERILITY, 2001, 75 (06) :1080-1087
[3]   Tibolone: Prevention of bone loss in late postmenopausal women [J].
Bjarnason, NH ;
Bjarnason, K ;
Haarbo, J ;
Rosenquist, C ;
Christiansen, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (07) :2419-2422
[4]   Controversies about HRT - lessons from monkey models [J].
Clarkson, TB ;
Appt, SE .
MATURITAS, 2005, 51 (01) :64-74
[5]  
DU ZJ, 1999, ACTA ACAD MED SINICA, V21, P280
[6]   Personal perspective on low-dosage estrogen therapy for postmenopausal women [J].
Ettinger, B .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 1999, 6 (03) :273-276
[7]   Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized, double-blind, placebo-controlled, dose-finding studies [J].
Gallagher, JC ;
Baylink, DJ ;
Freeman, R ;
McClung, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (10) :4717-4726
[8]   Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy [J].
Gambacciani, M ;
Ciaponi, M ;
Cappagli, B ;
Monteleone, P ;
Benussi, C ;
Bevilacqua, G ;
Genazzani, AR .
MATURITAS, 2003, 45 (03) :175-183
[9]  
GE Q, 5 INT C REPR END BEI, P19
[10]   A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women [J].
Haines, CJ ;
Yim, SF ;
Chung, TKH ;
Lam, CWK ;
Lau, EWC ;
Ng, MHL ;
Chin, R ;
Lee, DTS .
MATURITAS, 2003, 44 (03) :207-214